Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Jun 14, 2024 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Pharmaceutical Executive® provides insights and stories behind successful commercial strategies, research and development (R&D), market access and more, to its audience of pharmaceutical executives.

Jun 10, 2023 · Movers and shakers. As mentioned, Pfizer and AbbVie captured the top two spots again in the Pharma 50—the latter, notably, expected to maintain its solid momentum, even with Humira’s patent expiration this year, thanks to reinforcements Skyrizi for psoriasis (up 75.7% in sales in 2022 to $5.2 billion) and JAK inhibitor Rinvoq (with seven approvals so far, including rheumatoid arthritis and ...

Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.

Aug 16, 2024 · The importance of pre-approval information exchange (PIE) with payers and other strategic considerations to help navigate today’s market access challenges and regulatory requirements in bringing promising cell and gene therapies to the market.

Dec 25, 2024 · Central to the Mission. Harpreet Gill, vice president of real-world solutions - project management at ICON, discussesthe progress and challenges in advancing data-driven tools and approaches in decentralized clinical trials, where ongoing education remains paramount.

Jul 12, 2019 · Dealing and diversifying. The BMS-Celgene and Roche-Spark deals, along with Eli Lilly’s $8 billion acquisition of Loxo Oncology, may signal the start of a wave of M&A activity in the industry that will last into 2020, analysts say, as companies look to increase diversification into new areas and put more R&D resources into therapeutic niches with strong pricing power, such as rare diseases.